Nuvalent
of met all desired clinical characteristics phase selection as was based on the following preliminary profile presented considerations maintained steady state plasma levels at or above the target efficacy thresholds alk wild type and alk single and compound mutations in both the periphery and in the at steady state day key favorable tolerability suggested the potential for a highly alk selective sparing safety profile early anti tumor activity observed in alk positive patients across a wide dose range including at with objective responses observed in a i a heavily treated patients including those previously treated with one or more second generation or plus and those who were naive a patients with alk single and compound resistance mutations and are not shown due to predicted efficacy thresholds alk single mutation alk compound mutations alk naive alk single mutation patients with metastases in in models bearing hip alk divided by a alk respectively a ratio targets for exceed corresponding periphery values | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
February 2024
Slide
24 of 42
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
of met all desired clinical characteristics phase favorable tolerability was observed in preliminary profile presented patients enrolled across six dose levels as may was not reached no clinically significant exposure response relationships for safety and efficacy were observed wide therapeutic window was consistent with selective sparing design the dose level daily maintained steady state plasma levels above target efficacy thresholds i a a i i a i a a a a go me nes me yes target target wild type target periphery target wild type periphery data as for patients treated by data for cohort are not shown due to immaturity centra based hours once daily standard deviation on in in models and respectively values for a and divided by predicted human brain to plasma ratio respectively on file a source | Nuvalent
Investor Presentation
April 2024
of met all desired clinical characteristics phase selection as was based on the following preliminary profile presented considerations maintained steady state plasma levels at or above the target efficacy thresholds alk wild type and alk single and compound mutations in both the periphery and in the at steady state day key favorable tolerability suggested the potential for a highly alk selective sparing safety profile early anti tumor activity observed in alk positive patients across a wide dose range including at with objective responses observed in as heavily treated patients including those previously treated with one or more second generation is or plus and those who were naive patients with alk single and compound resistance mutations and are not shown due to immaturity predicted efficacy thresholds alk single mutation alk compound mutations alk naive alk single mutation patients with metastases predicted source lin in in models bearing hip alk divided by alk respectively targets for exceed corresponding periphery values | Nuvalent
Investor Presentation
February 2024
of met all desired clinical characteristics phase favorable tolerability was observed in preliminary profile presented patients enrolled across six dose levels as may was not reached no clinically significant exposure response relationships for safety and efficacy were observed wide therapeutic window was consistent with selective sparing design the dose level daily maintained steady state plasma levels above target efficacy thresholds i a a a a a a target target wild type target periphery target wild type periphery data as for patients treated by data for cohort are not shown due to immaturity central nervous system standard deviation hours once daily in models in and respectively based on tumor reg on source data on file a i values for a and divided by predicted human brain to plasma ratio respectively | Nuvalent
Investor Presentation
January 2024
of met all desired clinical characteristics phase favorable tolerability was observed in preliminary profile presented patients enrolled across six dose levels as may was not reached no clinically significant exposure response relationships for safety and efficacy were observed wide therapeutic window was consistent with selective sparing design the dose level daily maintained steady state plasma levels above target efficacy thresholds i a a a a a a target target wild type target periphery target wild type periphery data as for patients treated by data for cohort are not shown due to immaturity central nervous system hours once daily standard deviation based on tumor regression in in models bearing and respectively values for a and divided by predicted human brain to plasma ratio respectively source data on file a i | Nuvalent
Related slides by other companies
Ocuphire Pharma
Investor Presentation
August 2023
preclinical data oral blocks | Ocuphire Pharma
MAIA Biotechnology
Investor Presentation
July 2023
thio trial patients dosed to date | MAIA Biotechnology
Recursion Pharmaceuticals
Investor Day
January 2023
clinical well understood clinical safety with a drug like profile further confidence prior studies suggestive of potential therapeutic benefit | Recursion Pharmaceuticals
AstraZeneca
Results
November 2023
oncology highlights data at and reinforce leadership across types consolidating leading position in lung expanding into new types in duo beat conventional patients with metastases at showed complete response first inhibitor option for advanced endometrial benefit with in and subgroups best in class profile supports combination with broad potential in lines and other types | AstraZeneca
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io